Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

By Dunkel Petra   Chai Christina LL   Sperlágh Beáta   Huleatt Paul B   Mátyus Péter  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 9, 2012-09 ,pp. : 1267-1308

Informa Healthcare

Access to resources Recommend Favorite

Implications of Parkinson's Disease Pathophysiology for the Development of Cell Replacement Strategies and Drug Discovery in Neurodegenerative Diseases

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 7, 2012-11 ,pp. : 907-920

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Thematic Issue: Current Advances in Biochemistry, Medicinal Chemistry and Drug Development Strategies for Age-Related Neurodegenerative Diseases)

By  

Current Topics in Medicinal Chemistry, Vol. 15, Iss. 21, 2015-01 ,pp. : 2115-2115

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Drug Development in Thromboembolic Diseases: Regulatory and Methodological Approach

By  

Current Drug Discovery Technologies, Vol. 9, Iss. 2, 2012-06 ,pp. : 105-118

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Novel Genomic Blood Biomarkers for Neurodegenerative Diseases

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 9, Iss. 6, 2010-12 ,pp. : 669-678

Bentham Science Publishers

Access to resources Recommend Favorite